nach oben

Current Diabetes Reports

Erschienen in:

01.10.2019 | Microvascular Complications—Neuropathy (R Pop-Busui, Section Editor)

Epidemiology of Peripheral Neuropathy and Lower Extremity Disease in Diabetes

verfasst von: Caitlin W. Hicks, Elizabeth Selvin

Erschienen in: Current Diabetes Reports | Ausgabe 10/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Diabetic peripheral neuropathy eventually affects nearly 50% of adults with diabetes during their lifetime and is associated with substantial morbidity including pain, foot ulcers, and lower limb amputation. This review summarizes the epidemiology, risk factors, and management of diabetic peripheral neuropathy and related lower extremity complications.

Recent Findings

The prevalence of peripheral neuropathy is estimated to be between 6 and 51% among adults with diabetes depending on age, duration of diabetes, glucose control, and type 1 versus type 2 diabetes. The clinical manifestations are variable, ranging from asymptomatic to painful neuropathic symptoms. Because of the risk of foot ulcer (25%) and amputation associated with diabetic peripheral neuropathy, aggressive screening and treatment in the form of glycemic control, regular foot exams, and pain management are important. There is an emerging focus on lifestyle interventions including weight loss and physical activity as well.

Summary

The American Diabetes Association has issued multiple recommendation statements pertaining to diabetic neuropathies and the care of the diabetic foot. Given that approximately 50% of adults with diabetes will be affected by peripheral neuropathy in their lifetime, more diligent screening and management are important to reduce the complications and health care burden associated with the disease.

•• Pop-Busui R, Boulton AJ, Feldman EL, Bril V, Freeman R, Malik RA, et al. Diabetic neuropathy: a position statement by the American Diabetes Association. Diabetes Care. 2017;40(1):136–54. https://doi.org/10.2337/dc16-2042 This article describes the most recent position statment from the American Diabetes Association about the workup and management of diabetic neuropathy.CrossRefPubMed

Gregg EW, Gu Q, Williams D, de Rekeneire N, Cheng YJ, Geiss L, et al. Prevalence of lower extremity diseases associated with normal glucose levels, impaired fasting glucose, and diabetes among U.S. adults aged 40 or older. Diabetes Res Clin Pract. 2007;77(3):485–8. https://doi.org/10.1016/j.diabres.2007.01.005.CrossRefPubMed

Boulton AJ. Diabetic neuropathy and foot complications. Handb Clin Neurol. 2014;126:97–107. https://doi.org/10.1016/B978-0-444-53480-4.00008-4.CrossRefPubMed

Boulton AJ. The pathway to foot ulceration in diabetes. Med Clin North Am. 2013;97(5):775–90. https://doi.org/10.1016/j.mcna.2013.03.007.CrossRefPubMed

Kumar S, Ashe HA, Parnell LN, Fernando DJ, Tsigos C, Young RJ, et al. The prevalence of foot ulceration and its correlates in type 2 diabetic patients: a population-based study. Diabet Med. 1994;11(5):480–4.CrossRefPubMed

Margolis DJ, Jeffcoate W. Epidemiology of foot ulceration and amputation: can global variation be explained? Med Clin North Am. 2013;97(5):791–805. https://doi.org/10.1016/j.mcna.2013.03.008.CrossRefPubMed

Vileikyte L, Leventhal H, Gonzalez JS, Peyrot M, Rubin RR, Ulbrecht JS, et al. Diabetic peripheral neuropathy and depressive symptoms: the association revisited. Diabetes Care. 2005;28(10):2378–83. https://doi.org/10.2337/diacare.28.10.2378.CrossRefPubMed

Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393–403. https://doi.org/10.1056/NEJMoa012512.CrossRefPubMed

Albers JW, Pop-Busui R. Diabetic neuropathy: mechanisms, emerging treatments, and subtypes. Curr Neurol Neurosci Rep. 2014;14(8):473. https://doi.org/10.1007/s11910-014-0473-5.CrossRefPubMedPubMedCentral

10.

Dyck PJ, Albers JW, Andersen H, Arezzo JC, Biessels GJ, Bril V, et al. Diabetic polyneuropathies: update on research definition, diagnostic criteria and estimation of severity. Diabetes Metab Res Rev. 2011;27(7):620–8. https://doi.org/10.1002/dmrr.1226.CrossRefPubMed

11.

Partanen J, Niskanen L, Lehtinen J, Mervaala E, Siitonen O, Uusitupa M. Natural history of peripheral neuropathy in patients with non-insulin-dependent diabetes mellitus. N Engl J Med. 1995;333(2):89–94. https://doi.org/10.1056/NEJM199507133330203.CrossRefPubMed

12.

Jambart S, Ammache Z, Haddad F, Younes A, Hassoun A, Abdalla K, et al. Prevalence of painful diabetic peripheral neuropathy among patients with diabetes mellitus in the Middle East region. J Int Med Res. 2011;39(2):366–377.10.1177/147323001103900204.CrossRefPubMed

13.

Hall GC, Carroll D, Parry D, McQuay HJ. Epidemiology and treatment of neuropathic pain: the UK primary care perspective. Pain. 2006;122(1–2):156–62. https://doi.org/10.1016/j.pain.2006.01.030.CrossRefPubMed

14.

Dyck PJ, Kratz KM, Karnes JL, Litchy WJ, Klein R, Pach JM, et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. Neurology. 1993;43(4):817–24. https://doi.org/10.1212/wnl.43.4.817.CrossRefPubMed

15.

Davies M, Brophy S, Williams R, Taylor A. The prevalence, severity, and impact of painful diabetic peripheral neuropathy in type 2 diabetes. Diabetes Care. 2006;29(7):1518–22. https://doi.org/10.2337/dc05-2228.CrossRefPubMed

16.

Daousi C, MacFarlane IA, Woodward A, Nurmikko TJ, Bundred PE, Benbow SJ. Chronic painful peripheral neuropathy in an urban community: a controlled comparison of people with and without diabetes. Diabet Med. 2004;21(9):976–82. https://doi.org/10.1111/j.1464-5491.2004.01271.x.CrossRefPubMed

17.

Boulton AJ, Vinik AI, Arezzo JC, Bril V, Feldman EL, Freeman R, et al. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care. 2005;28(4):956–62. https://doi.org/10.2337/diacare.28.4.956.CrossRefPubMed

18.

Smith BE. Focal and entrapment neuropathies. Handb Clin Neurol. 2014;126:31–43. https://doi.org/10.1016/B978-0-444-53480-4.00003-5.CrossRefPubMed

19.

Dyck PJ, Windebank AJ. Diabetic and nondiabetic lumbosacral radiculoplexus neuropathies: new insights into pathophysiology and treatment. Muscle Nerve. 2002;25(4):477–91.CrossRefPubMed

20.

Massie R, Mauermann ML, Staff NP, Amrami KK, Mandrekar JN, Dyck PJ, et al. Diabetic cervical radiculoplexus neuropathy: a distinct syndrome expanding the spectrum of diabetic radiculoplexus neuropathies. Brain. 2012;135(Pt 10):3074–88. https://doi.org/10.1093/brain/aws244.CrossRefPubMed

21.

Gibbons CH, Freeman R. Treatment-induced neuropathy of diabetes: an acute, iatrogenic complication of diabetes. Brain. 2015;138(Pt 1):43–52. https://doi.org/10.1093/brain/awu307.CrossRefPubMed

22.

• Iqbal Z, Azmi S, Yadav R, Ferdousi M, Kumar M, Cuthbertson DJ, et al. Diabetic peripheral neuropathy: epidemiology, diagnosis, and pharmacotherapy. Clin Ther. 2018;40(6):828–49. https://doi.org/10.1016/j.clinthera.2018.04.001 This article provides a comprehensive literature review on the treatment of neuropathic pain in diabetic peripheral neuropathy. CrossRefPubMed

23.

Pirart J. Diabetes mellitus and its degenerative complications: a prospective study of 4,400 patients observed between 1947 and 1973 (3rd and last part) (author’s transl). Diabete Metab. 1977;3(2–4).

24.

Tesfaye S, Stevens LK, Stephenson JM, Fuller JH, Plater M, Ionescu-Tirgoviste C, et al. Prevalence of diabetic peripheral neuropathy and its relation to glycaemic control and potential risk factors: the EURODIAB IDDM Complications Study. Diabetologia. 1996;39(11):1377–84.CrossRefPubMed

25.

Abbott CA, Malik RA, van Ross ER, Kulkarni J, Boulton AJ. Prevalence and characteristics of painful diabetic neuropathy in a large community-based diabetic population in the U.K. Diabetes Care. 2011;34(10):2220–4. https://doi.org/10.2337/dc11-1108.CrossRefPubMedPubMedCentral

26.

Cabezas-Cerrato J. The prevalence of clinical diabetic polyneuropathy in Spain: a study in primary care and hospital clinic groups. Neuropathy Spanish Study Group of the Spanish Diabetes Society (SDS). Diabetologia. 1998;41(11):1263–9.CrossRefPubMed

27.

Martin CL, Albers JW, Pop-Busui R, Group DER. Neuropathy and related findings in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes Care. 2014;37(1):31–8. https://doi.org/10.2337/dc13-2114.CrossRefPubMed

28.

Maser RE, Steenkiste AR, Dorman JS, Nielsen VK, Bass EB, Manjoo Q, et al. Epidemiological correlates of diabetic neuropathy. Report from Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes. 1989;38(11):1456–61. https://doi.org/10.2337/diab.38.11.1456.CrossRefPubMed

29.

Jaiswal M, Lauer A, Martin CL, Bell RA, Divers J, Dabelea D, et al. Peripheral neuropathy in adolescents and young adults with type 1 and type 2 diabetes from the SEARCH for Diabetes in Youth follow-up cohort: a pilot study. Diabetes Care. 2013;36(12):3903–8. https://doi.org/10.2337/dc13-1213.CrossRefPubMedPubMedCentral

30.

Ismail-Beigi F, Craven T, Banerji MA, Basile J, Calles J, Cohen RM, et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet. 2010;376(9739):419–30. https://doi.org/10.1016/S0140-6736(10)60576-4.CrossRefPubMedPubMedCentral

31.

Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360(2):129–39. https://doi.org/10.1056/NEJMoa0808431.CrossRefPubMed

32.

Pop-Busui R, Lu J, Lopes N, Jones TL, Investigators BD. Prevalence of diabetic peripheral neuropathy and relation to glycemic control therapies at baseline in the BARI 2D cohort. J Peripher Nerv Syst. 2009;14(1):1–13. https://doi.org/10.1111/j.1529-8027.2009.00200.x.CrossRefPubMedPubMedCentral

33.

Tovi J, Svanborg E, Nilsson BY, Engfeldt P. Diabetic neuropathy in elderly type 2 diabetic patients: effects of insulin treatment. Acta Neurol Scand. 1998;98(5):346–53.CrossRefPubMed

34.

Young MJ, Boulton AJ, MacLeod AF, Williams DR, Sonksen PH. A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia. 1993;36(2):150–4.CrossRefPubMed

35.

Feldman EL, Nave KA, Jensen TS, Bennett DLH. New horizons in diabetic neuropathy: mechanisms, bioenergetics, and pain. Neuron. 2017;93(6):1296–313. https://doi.org/10.1016/j.neuron.2017.02.005.CrossRefPubMedPubMedCentral

36.

Sajic M. Mitochondrial dynamics in peripheral neuropathies. Antioxid Redox Signal. 2014;21(4):601–20. https://doi.org/10.1089/ars.2013.5822.CrossRefPubMed

37.

Green AQ, Krishnan S, Finucane FM, Rayman G. Altered C-fiber function as an indicator of early peripheral neuropathy in individuals with impaired glucose tolerance. Diabetes Care. 2010;33(1):174–6. https://doi.org/10.2337/dc09-0101.CrossRefPubMedPubMedCentral

38.

Malik RA, Veves A, Walker D, Siddique I, Lye RH, Schady W, et al. Sural nerve fibre pathology in diabetic patients with mild neuropathy: relationship to pain, quantitative sensory testing and peripheral nerve electrophysiology. Acta Neuropathol. 2001;101(4):367–74.PubMed

39.

Ang L, Jaiswal M, Martin C, Pop-Busui R. Glucose control and diabetic neuropathy: lessons from recent large clinical trials. Curr Diab Rep. 2014;14(9):528. https://doi.org/10.1007/s11892-014-0528-7.CrossRefPubMedPubMedCentral

40.

Diabetes Control and Complications Trial Research Group, Nathan DM, Genuth S, Lachin J, Cleary P, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977–86. https://doi.org/10.1056/NEJM199309303291401.CrossRef

41.

Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28(2):103–17.CrossRefPubMed

42.

Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577–89. https://doi.org/10.1056/NEJMoa0806470.CrossRefPubMed

43.

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):854–865.

44.

Callaghan BC, Little AA, Feldman EL, Hughes RA. Enhanced glucose control for preventing and treating diabetic neuropathy. Cochrane Database Syst Rev. 2012;(6):CD007543.https://doi.org/10.1002/14651858.CD007543.pub2.

45.

Tesfaye S, Chaturvedi N, Eaton SE, Ward JD, Manes C, Ionescu-Tirgoviste C, et al. Vascular risk factors and diabetic neuropathy. N Engl J Med. 2005;352(4):341–50. https://doi.org/10.1056/NEJMoa032782.CrossRefPubMed

46.

Wiggin TD, Sullivan KA, Pop-Busui R, Amato A, Sima AA, Feldman EL. Elevated triglycerides correlate with progression of diabetic neuropathy. Diabetes. 2009;58(7):1634–40. https://doi.org/10.2337/db08-1771.CrossRefPubMedPubMedCentral

47.

Pinto A, Tuttolomondo A, Di Raimondo D, Fernandez P, La Placa S, Di Gati M, et al. Cardiovascular risk profile and morbidity in subjects affected by type 2 diabetes mellitus with and without diabetic foot. Metabolism. 2008;57(5):676–82. https://doi.org/10.1016/j.metabol.2008.01.004.CrossRefPubMed

48.

Hanewinckel R, Ikram MA, Van Doorn PA. Peripheral neuropathies. Handb Clin Neurol. 2016;138:263–82. https://doi.org/10.1016/B978-0-12-802973-2.00015-X.CrossRefPubMed

49.

Albers JW, Brown MB, Sima AA, Greene DA. Frequency of median mononeuropathy in patients with mild diabetic neuropathy in the early diabetes intervention trial (EDIT). Tolrestat Study Group For Edit (Early Diabetes Intervention Trial). Muscle Nerve. 1996;19(2):140–6. https://doi.org/10.1002/(SICI)1097-4598(199602)19:2<140::AID-MUS3>3.0.CO;2-E.CrossRefPubMed

50.

O’Hare JA, Abuaisha F, Geoghegan M. Prevalence and forms of neuropathic morbidity in 800 diabetics. Ir J Med Sci. 1994;163(3):132–5.CrossRefPubMed

51.

Vinik AI, Holland MT, Le Beau JM, Liuzzi FJ, Stansberry KB, Colen LB. Diabetic neuropathies. Diabetes Care. 1992;15(12):1926–75. https://doi.org/10.2337/diacare.15.12.1926.CrossRefPubMed

52.

Vinik A, Mehrabyan A, Colen L, Boulton A. Focal entrapment neuropathies in diabetes. Diabetes Care. 2004;27(7):1783–8. https://doi.org/10.2337/diacare.27.7.1783.CrossRefPubMed

53.

Zhang P, Lu J, Jing Y, Tang S, Zhu D, Bi Y. Global epidemiology of diabetic foot ulceration: a systematic review and meta-analysis (dagger). Ann Med. 2017;49(2):106–16. https://doi.org/10.1080/07853890.2016.1231932.CrossRefPubMed

54.

Singh N, Armstrong DG, Lipsky BA. Preventing foot ulcers in patients with diabetes. JAMA. 2005;293(2):217–28. https://doi.org/10.1001/jama.293.2.217.CrossRefPubMed

55.

Hicks CW, Selvarajah S, Mathioudakis N, Sherman RE, Hines KF, Black JH 3rd, et al. Burden of infected diabetic foot ulcers on hospital admissions and costs. Ann Vasc Surg. 2016;33:149–58. https://doi.org/10.1016/j.avsg.2015.11.025.CrossRefPubMedPubMedCentral

56.

American Association of Diabetes, Consensus Development Conference on Diabetic Foot Wound Care: 7–8 April 1999, Boston, Massachusetts. Am Diabetes Assoc Diabetes Care. 1999;22(8):1354–60. https://doi.org/10.2337/diacare.22.8.1354.

57.

Brem H, Sheehan P, Rosenberg HJ, Schneider JS, Boulton AJ. Evidence-based protocol for diabetic foot ulcers. Plast Reconstr Surg. 2006;117(7 Suppl):193S–209S; discussion 210S–211S. https://doi.org/10.1097/01.prs.0000225459.93750.29.CrossRefPubMed

58.

Boodoo C, Perry JA, Leung G, Cross KM, Isaranuwatchai W. Cost-effectiveness of telemonitoring screening for diabetic foot ulcer: a mathematical model. CMAJ Open. 2018;6(4):E486-E494.https://doi.org/10.9778/cmajo.20180088 CrossRefPubMedPubMedCentral

59.

Lim JZ, Ng NS, Thomas C. Prevention and treatment of diabetic foot ulcers. J R Soc Med. 2017;110(3):104–109.10.1177/0141076816688346.CrossRefPubMedPubMedCentral

60.

•• American Association of Diabetes. 11. Microvascular complications and foot care: standards of medical care in diabetes-2019. Diabetes Care. 2019;42(Suppl 1):S124–38. https://doi.org/10.2337/dc19-S011 This article describes the most recent recommendations from the American Diabetes Association about the workup and management of microvascular complications and foot care in adults with diabetes.CrossRef

61.

Boulton AJ. Lowering the risk of neuropathy, foot ulcers and amputations. Diabet Med. 1998;15(Suppl 4):S57–9. https://doi.org/10.1002/(SICI)1096-9136(1998120)15:4+<S57::AID-DIA741>3.0.CO;2-D.CrossRefPubMed

62.

Boulton AJ, Kempler P, Ametov A, Ziegler D. Whither pathogenetic treatments for diabetic polyneuropathy? Diabetes Metab Res Rev. 2013;29(5):327–33. https://doi.org/10.1002/dmrr.2397.CrossRefPubMed

63.

Smith AG, Russell J, Feldman EL, Goldstein J, Peltier A, Smith S, et al. Lifestyle intervention for pre-diabetic neuropathy. Diabetes Care. 2006;29(6):1294–9. https://doi.org/10.2337/dc06-0224.CrossRefPubMed

64.

Bril V, England J, Franklin GM, Backonja M, Cohen J, Del Toro D, et al. Evidence-based guideline: treatment of painful diabetic neuropathy: report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. PM R. 2011;3(4):345–52, 352 e341–321. https://doi.org/10.1016/j.pmrj.2011.03.008.CrossRefPubMed

65.

Onakpoya IJ, Thomas ET, Lee JJ, Goldacre B, Heneghan CJ. Benefits and harms of pregabalin in the management of neuropathic pain: a rapid review and meta-analysis of randomised clinical trials. BMJ Open. 2019;9(1):e023600. https://doi.org/10.1136/bmjopen-2018-023600.CrossRefPubMedPubMedCentral

66.

Ormseth MJ, Scholz BA, Boomershine CS. Duloxetine in the management of diabetic peripheral neuropathic pain. Patient Prefer Adherence. 2011;5:343–56. https://doi.org/10.2147/PPA.S16358.CrossRefPubMedPubMedCentral

67.

Kvinesdal B, Molin J, Froland A, Gram LF. Imipramine treatment of painful diabetic neuropathy. JAMA. 1984;251(13):1727–30.CrossRefPubMed

68.

Max MB, Culnane M, Schafer SC, Gracely RH, Walther DJ, Smoller B, et al. Amitriptyline relieves diabetic neuropathy pain in patients with normal or depressed mood. Neurology. 1987;37(4):589–96. https://doi.org/10.1212/wnl.37.4.589.CrossRefPubMed

69.

Gimbel JS, Richards P, Portenoy RK. Controlled-release oxycodone for pain in diabetic neuropathy: a randomized controlled trial. Neurology. 2003;60(6):927–34. https://doi.org/10.1212/01.wnl.0000057720.36503.2c.CrossRefPubMed

70.

Harati Y, Gooch C, Swenson M, Edelman S, Greene D, Raskin P, et al. Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy. Neurology. 1998;50(6):1842–6. https://doi.org/10.1212/wnl.50.6.1842.CrossRefPubMed

71.

Hojsted J, Sjogren P. Addiction to opioids in chronic pain patients: a literature review. Eur J Pain. 2007;11(5):490–518. https://doi.org/10.1016/j.ejpain.2006.08.004.CrossRefPubMed

72.

Patil PR, Wolfe J, Said Q, Thomas J, Martin BC. Opioid use in the management of diabetic peripheral neuropathy (DPN) in a large commercially insured population. Clin J Pain. 2015;31(5):414–24. https://doi.org/10.1097/AJP.0000000000000124.CrossRefPubMedPubMedCentral

73.

Zhao Y, Wu N, Chen S, Boulanger L, Police RL, Fraser K. Changes in opioid use and healthcare costs among U.S. patients with diabetic peripheral neuropathic pain treated with duloxetine compared with other therapies. Curr Med Res Opin. 2010;26(9):2147–56. https://doi.org/10.1185/03007995.2010.503140.CrossRefPubMed

74.

Wu N, Chen S, Boulanger L, Fraser K, Bledsoe SL, Zhao Y. Duloxetine compliance and its association with healthcare costs among patients with diabetic peripheral neuropathic pain. J Med Econ. 2009;12(3):192–202. https://doi.org/10.3111/13696990903240559.CrossRefPubMed

75.

Martell BA, O’Connor PG, Kerns RD, Becker WC, Morales KH, Kosten TR, et al. Systematic review: opioid treatment for chronic back pain: prevalence, efficacy, and association with addiction. Ann Intern Med. 2007;146(2):116–27. https://doi.org/10.7326/0003-4819-146-2-200701160-00006.CrossRefPubMed

76.

Gordois A, Scuffham P, Shearer A, Oglesby A, Tobian JA. The health care costs of diabetic peripheral neuropathy in the US. Diabetes Care. 2003;26(6):1790–5. https://doi.org/10.2337/diacare.26.6.1790.CrossRefPubMed

77.

Hicks CW, Selvarajah S, Mathioudakis N, Perler BA, Freischlag JA, Black JH 3rd, et al. Trends and determinants of costs associated with the inpatient care of diabetic foot ulcers. J Vasc Surg. 2014;60(5):1247–1254 e1242. https://doi.org/10.1016/j.jvs.2014.05.009.CrossRefPubMedPubMedCentral

78.

Van Acker K, Bouhassira D, De Bacquer D, Weiss S, Matthys K, Raemen H, et al. Prevalence and impact on quality of life of peripheral neuropathy with or without neuropathic pain in type 1 and type 2 diabetic patients attending hospital outpatients clinics. Diabetes Metab. 2009;35(3):206–13. https://doi.org/10.1016/j.diabet.2008.11.004.CrossRefPubMed

79.

Tolle T, Xu X, Sadosky AB. Painful diabetic neuropathy: a cross-sectional survey of health state impairment and treatment patterns. J Diabetes Complications. 2006;20(1):26–33. https://doi.org/10.1016/j.jdiacomp.2005.09.007.CrossRefPubMed

80.

McDermott AM, Toelle TR, Rowbotham DJ, Schaefer CP, Dukes EM. The burden of neuropathic pain: results from a cross-sectional survey. Eur J Pain. 2006;10(2):127–35. https://doi.org/10.1016/j.ejpain.2005.01.014.CrossRefPubMed

81.

Timar B, Timar R, Gaita L, Oancea C, Levai C, Lungeanu D. The impact of diabetic neuropathy on balance and on the risk of falls in patients with type 2 diabetes mellitus: a cross-sectional study. PLoS One. 2016;11(4):e0154654. https://doi.org/10.1371/journal.pone.0154654.CrossRefPubMedPubMedCentral

82.

Brown SJ, Handsaker JC, Bowling FL, Boulton AJ, Reeves ND. Diabetic peripheral neuropathy compromises balance during daily activities. Diabetes Care. 2015;38(6):1116–22. https://doi.org/10.2337/dc14-1982.CrossRefPubMed

83.

Schwartz AV, Vittinghoff E, Sellmeyer DE, Feingold KR, de Rekeneire N, Strotmeyer ES, et al. Diabetes-related complications, glycemic control, and falls in older adults. Diabetes Care. 2008;31(3):391–6. https://doi.org/10.2337/dc07-1152.CrossRefPubMed

84.

Schneider AL, Williams EK, Brancati FL, Blecker S, Coresh J, Selvin E. Diabetes and risk of fracture-related hospitalization: the Atherosclerosis Risk in Communities Study. Diabetes Care. 2013;36(5):1153–8. https://doi.org/10.2337/dc12-1168.CrossRefPubMedPubMedCentral

85.

Yang Y, Hu X, Zhang Q, Zou R. Diabetes mellitus and risk of falls in older adults: a systematic review and meta-analysis. Age Ageing. 2016;45(6):761–7. https://doi.org/10.1093/ageing/afw140.CrossRefPubMed

86.

Janghorbani M, Van Dam RM, Willett WC, Hu FB. Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol. 2007;166(5):495–505. https://doi.org/10.1093/aje/kwm106.CrossRefPubMed

87.

Kim JH, Jung MH, Lee JM, Son HS, Cha BY, Chang SA. Diabetic peripheral neuropathy is highly associated with nontraumatic fractures in Korean patients with type 2 diabetes mellitus. Clin Endocrinol (Oxf). 2012;77(1):51–5. https://doi.org/10.1111/j.1365-2265.2011.04222.x.CrossRefPubMed

88.

Selvin E, Narayan KM, Huang ES. Chapter 41: Quality of care in people with diabetes. In: Cowie CCCS, Menke A, Cissell MA, Eberhardt MS, Meigs JB, Gregg EW, Knowler WC, Barrett-Connor E, Becker DJ, Brancati FL, Boyko EJ, Herman WH, Howard BV, Narayan KMV, Rewers M, Fradkin JE, editors. Diabetes in America, 3rd ed. NIH Pub No. 17–1468. 3rd ed. Bethesda, MD: National Institutes of Health; 2018.

89.

Centers for Disease Control and Prevention (CDC). Age-adjusted percentage of adults aged 18 years or older with diagnosed diabetes receiving a foot exam in the last year, United States, 1994–2010 https://www.cdc.gov/diabetes/statistics/preventive/fx_foot.htm2014 Last updated 2014. Accessed 03/07/2019.

90.

Centers for Medicare and Medicaid Services (CMS). Proposed clinical quality measures for 2014. http://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/QualityMeasures/Downloads/Eligible-Providers-2014-Proposed-EHR-Incentive-Program-CQM.pdf 2014 Updated 2014. Accessed 03/02/2019.

91.

Miller JD, Carter E, Shih J, Giovinco NA, Boulton AJ, Mills JL, et al. How to do a 3-minute diabetic foot exam. J Fam Pract. 2014;63(11):646–56.PubMed

92.

American Association of Diabetes. Peripheral arterial disease in people with diabetes. Diabetes Care. 2003;26(12):3333–41. https://doi.org/10.2337/diacare.26.12.3333.CrossRef

Titel: Epidemiology of Peripheral Neuropathy and Lower Extremity Disease in Diabetes
verfasst von: Caitlin W. Hicks
Elizabeth Selvin
Publikationsdatum: 01.10.2019
Verlag: Springer US
Erschienen in: Current Diabetes Reports / Ausgabe 10/2019
Print ISSN: 1534-4827
Elektronische ISSN: 1539-0829
DOI: https://doi.org/10.1007/s11892-019-1212-8

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2019

Association Between Antipsychotic Medication Use and Diabetes

Novel Preparations of Glucagon for the Prevention and Treatment of Hypoglycemia

Pharmacological Modulation of Ghrelin to Induce Weight Loss: Successes and Challenges

Letter to the Editor: Reflections on: “Perioperative Management of Diabetes Mellitus: Novel Approaches”

Surgical Innovations in the Treatment of Diabetic Macular Edema and Diabetic Retinopathy

Inpatient Management of T2DM and Hyperglycemia in Older Adults